Bank of America
CELZ icon

Bank of America’s Creative Medical Technology CELZ Stock Holding History

Bank of America’s Portfolio CELZ Stock Details CELZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-5,132
Closed -$10.1K – 5908
2025
Q4 		$10.1K Buy
5,132
+5,001
+3,818% +$14.8K ﹤0.01% 6162
2025
Q3 		$436 Sell
131
-2
-2% -$6 ﹤0.01% 7614
2025
Q2 		$352 Buy
133
+11
+9% +$24 ﹤0.01% 7732
2025
Q1 		$264 Hold
122
– – ﹤0.01% 7634
2024
Q4 		$281 Sell
122
-9
-7% -$27 ﹤0.01% 7519
2024
Q3 		$406 Buy
131
+2
+2% +$7 ﹤0.01% 7423
2024
Q2 		$496 Buy
129
+21
+19% +$95 ﹤0.01% 7365
2024
Q1 		$563 Buy
+108
New +$503 ﹤0.01% 7266
2023
Q2 		– Sell
-108
Closed -$538 – 7725
2023
Q1 		$538 Hold
108
– – ﹤0.01% 7363
2022
Q4 		$410 Hold
108
– – ﹤0.01% 7460
2022
Q3 		$0 Hold
108
– – ﹤0.01% 7860
2022
Q2 		$1K Hold
108
– – ﹤0.01% 7849
2022
Q1 		$4K Buy
+108
New +$2.4K ﹤0.01% 7926

Other funds holding CELZ

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.25% 1-Year Est. Return

Bank of America's CELZ Position: Q1 2026 in Review

Bank of America sold out of Creative Medical Technology (CELZ) in Q1 2026, closing a stake of 5,132 shares — an estimated $10.1K sold.

Bank of America first reported a position in CELZ in Q1 2022 and held it in 13 quarters. The position peaked at $10.1K in Q4 2025. 11 funds tracked by Wall St. Rank hold CELZ as of Q1 2026.

  • Bank of America reported no remaining Creative Medical Technology position as of Q1 2026 after selling out during the quarter.
  • Bank of America sold 5,132 Creative Medical Technology shares in Q1 2026, an estimated $10.1K.
  • Bank of America first reported a position in Creative Medical Technology in Q1 2022 and held it in 13 quarters.
  • Bank of America's Creative Medical Technology position peaked at $10.1K in Q4 2025.
  • 11 funds tracked by Wall St. Rank held Creative Medical Technology as of Q1 2026.

Based on Bank of America's 13F filing for Q1 2026, filed 18 May 2026.